How IDH-Mutant Glioma Turns Aggressive: The Epigenetic Shift That Drives Brain Cancer Progression

The Core Mechanism: Progressive Hypomethylation Drives Stem-Like States

These tumors begin with a CpG island methylator phenotype (G-CIMP) — an abnormally high level of DNA methylation marks that silence genes . Over time, the study showed, these tumors progressively lose DNA methylation marks (hypomethylation). Crucially, this loss is not random: it is invariably associated with malignant progression and occurs across all cancer cells in the tumor .

The loss of methylation leads to the aberrant unsilencing of genes normally active only in neural stem cells. This pushes glioma cells into immature, stem-cell-like states — specifically, neural progenitor cell-like (NPC-like) states — that are more plastic, proliferative, invasive, and resistant to treatment .

Low-grade tumors are dominated by slow-cycling oligodendrocyte progenitor cell (OPC)-like states. During progression, a more proliferative NPC-like population expands, and this shift is directly accompanied by the progressive loss of DNA methylation .

Why Vorasidenib Only Helps Some Patients

Vorasidenib is a brain-penetrant dual inhibitor of mutant IDH1/2 that was approved by the FDA in August 2024 for grade 2 IDH-mutant gliomas . It works by nudging glioma cells toward more differentiated, slower-growing states . However, the drug appears to benefit only a subset of patients.

The study's findings provide a testable explanation. Tumors with more advanced hypomethylation may be locked into stem-like states that are less responsive to differentiation-promoting therapy. As Dr. Suvà stated in the Weill Cornell press release: "A possibility we hope to investigate in future research is that the non-responding gliomas have more hypomethylation, which makes it harder for the drug to work" .

Future Prognostic Markers and Therapeutic Targets

The degree of DNA hypomethylation — and the corresponding expansion of NPC-like cell states — could serve as a molecular marker for grading aggressiveness and predicting progression risk . This could help clinicians identify which patients are likely to progress rapidly and which may benefit most from vorasidenib.

The aberrantly unsilenced stem-cell genes and the epigenetic machinery driving hypomethylation represent new therapeutic vulnerabilities. Strategies to reverse or halt hypomethylation, or to target the stem-like cell states directly, could complement IDH inhibitors . The study also highlights that this single-cell multimodal profiling approach provides a template for studying treatment resistance and progression in other cancers .